Source: Annual Congress 2012 - Treatment of lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
T. Wibmer, T. Berghmans, C. Kropf, J.J. Lafitte, K.M. Stoiber, M. Paesmans, S. Ruediger, A. Scherpereel, I. Blanta, W. Rottbauer, J.P. Sculier, C. Schumann (Ulm, Germany; Brussels, Belgium; Lille, France). Histology as a potential clinical predictor of outcome in advanced non-small cell lung cancer (NSCLC) treated with vinorelbine and mitomycin (VM) combination chemotherapy. Eur Respir J 2012; 40: Suppl. 56, 3264

Member's Comments

No comment yet.

Related content which might interest you: Gemcitabine and cisplatin ( GD) as first line chemotherapy in patients with non-small-cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 464s Year: 2002 Implementation study: role of docetaxel after a first line cisplatinum based chemotherapy for non-small cell lung cancer (NSCLC) Source: Eur Respir J 2004; 24: Suppl. 48, 303s Year: 2004 Lung function evaluation in gemcitabine and concurrent radiotherapy treatment in nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 376s Year: 2001 Vinorelbin and cisplatin in the treatment of advanced stage non-small cell lung cancer: Indian experience Source: Annual Congress 2008 - Treatment of thoracic tumours Year: 2008 Biweekly administration of docetaxel and gemcitabine for elderly patients with advanced non-small cell lung cancer (NSCLC). A phase II study Source: Eur Respir J 2006; 28: Suppl. 50, 772s Year: 2006 Second-line weekly paclitaxel in advanced nonsmall cell lung cancer (NSCLC) Source: Annual Congress 2003 - Advanced lung cancer treatment Year: 2003 Low dosage chemotherapy, with carboplatin (CBDCA) and vinorelbine (VNR), in advanced nonsmall cell lung cancer (NSCLC) in patients with low performance status Source: Eur Respir J 2003; 22: Suppl. 45, 528s Year: 2003 Docetaxel in combination with cisplatin in patients with advanced non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 302s Year: 2004 Efficacy and safety of Pemetrexed (PEM) for elderly patients with advanced non-small cell lung cancer (NSCLC) who had previous chemotherapy Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 Gemcitabine, ifosfamide and paclitaxel in patients with untreated advanced/metastatic nonsmall cell lung cancer (NSCLC) A phase II study Source: Eur Respir J 2003; 22: Suppl. 45, 28s Year: 2003 Chemotherapy with carboplatin and gemcitabine in patients with non resectable stages of non-small cell lung cancer (non-SCLC) Source: Eur Respir J 2007; 30: Suppl. 51, 436s Year: 2007 Treatment of advanced non-small cell lung cancer Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment Year: 2005 The comparison of paclitaxel-carboplatin (PCp) versus gemcitabine-cisplatin (GC) in the treatment of locally advanced or metastatic non-small cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 464s Year: 2002 Should patients with metastatic NSCLC and poor performance status be treated by chemotherapy? Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies Year: 2007 Locally advanced inoperable non-small cell lung cancer (NSCLC) treated by weekly paclitaxel/carboplatin chemotherapy with concomitant radiotherapy Source: Eur Respir J 2007; 30: Suppl. 51, 433s Year: 2007 Phase I trial of lipoplatinÔ and gemcitabine as second line chemotherapy in patients with refractory or resistant advanced non-small-cell lung carcinoma (NSCLC) Source: Eur Respir J 2007; 30: Suppl. 51, 241s Year: 2007 Role of chemotherapy in stage III non-small cell lung cancer (NSCLC): adjuvant or induction? Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer Year: 2006 Gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 64s Year: 2003 Concurrent paclitaxel, carboplatin and radiation therapy for locally advanced non-small cell lung cancer (NSCLC), a phase II multi-institutional trial Source: Eur Respir J 2002; 20: Suppl. 38, 187s Year: 2002 Hyper-progressive disease in patients with advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo) Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018